Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19021882 | STABLE PHARMACEUTICAL COMPOSITIONS OF CLONIDINE | January 2025 | July 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18912152 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | October 2024 | November 2025 | Allow | 13 | 3 | 1 | Yes | Yes |
| 18910243 | SKINCARE COOLING PRODUCT, METHOD OF MAKING, AND METHOD OF USING THE SAME | October 2024 | April 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18739871 | HORTICULTURAL HYDROGELS | June 2024 | December 2024 | Allow | 6 | 2 | 0 | No | No |
| 18703622 | PERFUMING COMPLEX, PERFUMING COMPOSITION AND PERFUMED AQUEOUS COMPOSITION OF NATURAL ORIGIN | April 2024 | March 2025 | Allow | 10 | 1 | 0 | No | No |
| 18637675 | Fibrous Structures Comprising Particles and Methods for Making Same | April 2024 | July 2025 | Allow | 15 | 0 | 0 | No | No |
| 18607924 | CO-CROSSLINKED HYALURONIC ACID-SILK FIBROIN HYDROGELS FOR IMPROVING TISSUE GRAFT VIABILITY AND FOR SOFT TISSUE AUGMENTATION | March 2024 | December 2025 | Allow | 21 | 1 | 0 | No | No |
| 18290914 | STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF | January 2024 | March 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18400346 | ORALLY AVAILABLE ARTICLES CONTAINING AT LEAST ONE STABILIZED SUPPLEMENT THEREIN | December 2023 | December 2024 | Allow | 11 | 0 | 1 | No | No |
| 18541510 | PHARMACEUTICAL COMPOSITIONS FOR VAPORIZATION AND INHALATION | December 2023 | October 2024 | Abandon | 10 | 0 | 1 | No | No |
| 18538617 | DETERGENT COMPOSITIONS FOR WASHING URUSHIOL AND METHODS OF TREATING URUSHIOL INDUCED CONTACT DERMATITIS | December 2023 | February 2025 | Allow | 14 | 1 | 0 | No | No |
| 18498005 | MANUFACTURING METHOD OF CASING | October 2023 | March 2025 | Abandon | 16 | 1 | 0 | Yes | No |
| 18488513 | AMORPHOUS SOLID DISPERSIONS | October 2023 | September 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18286774 | ANTIMICROBIAL COMPOSITION | October 2023 | March 2025 | Abandon | 17 | 2 | 0 | No | No |
| 18468199 | AMORPHOUS SOLID DISPERSIONS | September 2023 | April 2025 | Allow | 19 | 1 | 1 | No | No |
| 18234755 | SYSTEM FOR MIXING GERMICIDALLY ACTIVE SOLUTIONS, ON-SITE, FOR DAIRY/AGRICULTURAL HYGIENE PURPOSES | August 2023 | February 2024 | Allow | 6 | 1 | 0 | No | No |
| 18365607 | SKIN DOUGH COMPOSITION | August 2023 | August 2025 | Allow | 25 | 4 | 1 | Yes | Yes |
| 18275651 | EMULSIFIED COMPOSITION AND COSMETIC MATERIAL | August 2023 | December 2025 | Allow | 29 | 1 | 0 | No | No |
| 18225849 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | July 2023 | August 2024 | Allow | 13 | 0 | 0 | No | No |
| 18262846 | Composition for the Drying of Tillandsia sp | July 2023 | December 2025 | Allow | 29 | 1 | 0 | Yes | No |
| 18224958 | NON-THERAPEUTIC USE OF A BIODEGRADABLE HYDROCARBON OIL | July 2023 | November 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18002190 | FORMULATION COMPRISING CANNABINOIDS | July 2023 | February 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18221784 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | July 2023 | April 2024 | Allow | 9 | 0 | 0 | Yes | No |
| 18345797 | AQUEOUS COSMETIC | June 2023 | March 2025 | Abandon | 20 | 1 | 1 | No | No |
| 18256338 | INCREASED SOLUBILIZATION OF ETHYLHEXYL TRIAZONE | June 2023 | December 2025 | Allow | 30 | 1 | 0 | No | No |
| 18323115 | NEW PHARMACEUTICAL DEVICE FOR USE IN INTRANASAL ADMINISTRATION | May 2023 | March 2025 | Allow | 21 | 3 | 1 | Yes | No |
| 18195712 | 1,2-ALKANEDIOLS AND A PROCESS FOR THEIR PRODUCTION | May 2023 | March 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18136443 | PHARMACEUTICAL SUSPENSIONS FOR BISMUTH SUBSALICYLATES | April 2023 | November 2025 | Allow | 31 | 3 | 1 | No | No |
| 18188537 | COMPOSITION FOR TREATING ATOPY OR PRURITUS COMPRISING N-ACETYL OR N-ACYL AMINO ACID | March 2023 | March 2025 | Abandon | 24 | 2 | 0 | Yes | No |
| 18026663 | MOISTURIZING ANTIBACTERIAL COMPOSITION | March 2023 | April 2025 | Abandon | 25 | 4 | 0 | No | No |
| 18013141 | METHOD FOR INCORPORATING ORGANIC COMPOUNDS IN SOLUTION WITHIN A HYDROGEL | February 2023 | July 2025 | Allow | 31 | 0 | 0 | No | No |
| 18091736 | PHARMACEUTICAL FORMULATIONS OF QUINOLINES | December 2022 | May 2024 | Allow | 17 | 2 | 1 | Yes | No |
| 18013770 | PHARMACEUTICAL COMPOSITION COMPRISING ORGANOID AND ANTI-INFLAMMATORY AGENT FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE | December 2022 | May 2023 | Allow | 4 | 0 | 0 | No | No |
| 18081979 | COMPOSITION FOR INHIBITING ALPHA-GLUCOSIDASE AND APPLICATION THEREOF | December 2022 | July 2023 | Allow | 7 | 1 | 0 | No | No |
| 18009451 | AMPHIPHILIC ALGINIC ACID PARTICLE GROUP AND METHOD FOR PRODUCING SAME | December 2022 | August 2025 | Allow | 32 | 0 | 0 | No | No |
| 17998701 | SHELL-FREE STABLE DISPERSION | November 2022 | March 2026 | Allow | 40 | 1 | 1 | Yes | No |
| 17986552 | FABRICATION OF NANOWIRES AND HIERARCHICALLY POROUS MATERIALS THROUGH SUPERCRITICAL CO2 ASSISTED NEBULIZATION | November 2022 | November 2024 | Allow | 24 | 1 | 0 | No | No |
| 18048417 | PARTICULATE SILICA SILYLATE KIT FOR TREATMENT OF SURFACES FOR HYDROPHOBICITY CHARACTERISTICS | October 2022 | September 2025 | Allow | 35 | 0 | 1 | Yes | No |
| 17914761 | FUNCTIONAL MATERIAL AND METHOD FOR PRODUCING SAME | September 2022 | March 2026 | Allow | 42 | 1 | 1 | No | No |
| 17905947 | COSMETIC COMPOSITION | September 2022 | November 2025 | Allow | 38 | 1 | 0 | No | No |
| 17802885 | COMPOSITION FOR DISPERSING A LIPOSOLUBLE COMPOUND IN AN AQUEOUS PHASE | August 2022 | March 2025 | Allow | 31 | 0 | 0 | No | No |
| 17891835 | TOPICAL THERAPEUTIC FORMULATIONS | August 2022 | March 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 17799972 | METHOD OF INCREASING THE FOAMING PROPERTIES OF DETERGENT COMPOSITIONS BY USE OF SACCHARIDE ISOMERATE | August 2022 | August 2025 | Allow | 36 | 1 | 0 | No | No |
| 17877522 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE AS CONTRACEPTIVE | July 2022 | December 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17795622 | HERBICIDE COMBINATIONS COMPRISING GLUFOSINATE AND SELECTED PPO INHIBITORS | July 2022 | September 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17795630 | Herbicide Combinations Comprising Glufosinate and Carfentrazone-Ethyl | July 2022 | September 2025 | Allow | 38 | 1 | 1 | No | No |
| 17866115 | STABLE PHARMACEUTICAL COMPOSITIONS OF CLONIDINE | July 2022 | October 2024 | Allow | 28 | 3 | 1 | Yes | No |
| 17812068 | FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USE | July 2022 | September 2023 | Allow | 14 | 1 | 1 | No | No |
| 17791249 | ANTIMICROBIAL FIBRES | July 2022 | October 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17855206 | COMPOSITION FOR STIMULATING FACIAL HAIR GROWTH AND METHODS OF MANUFACTURING A COMPOSITION FOR STIMULATING FACIAL HAIR GROWTH | June 2022 | January 2024 | Allow | 19 | 3 | 1 | Yes | No |
| 17788215 | POWDERY SOLID COSMETIC PREPARATION | June 2022 | December 2025 | Allow | 41 | 2 | 0 | Yes | No |
| 17785784 | PHARMACEUTICAL COMPOSITION OF CYCLOOXYGENASE - 2 INHIBITORS | June 2022 | September 2025 | Allow | 39 | 1 | 1 | No | No |
| 17834260 | FIXED DOSE PHARMACEUTICAL COMPOSITION OF VALSARTAN AND SACUBITRIL | June 2022 | July 2023 | Allow | 13 | 1 | 0 | No | No |
| 17748886 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | May 2022 | February 2023 | Allow | 9 | 1 | 1 | No | No |
| 17776653 | PHYTOSANITARY AGENT AND ITS PARTICULAR USE IN THE TREATMENT OF PLANTS INFECTED BY XYLELLA FASTIDIOSA | May 2022 | November 2025 | Allow | 42 | 1 | 1 | No | No |
| 17733797 | FIBER-HYDROGEL COMPOSITE SURGICAL MESHES FOR TISSUE REPAIR | April 2022 | October 2025 | Allow | 41 | 2 | 0 | No | No |
| 17770574 | METHODS FOR WEED GROWTH CONTROL | April 2022 | May 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 17721699 | SYNTHESIS OF TAUROLIDINE, PURITY PROFILES AND POLYMORPHS | April 2022 | April 2023 | Allow | 12 | 3 | 0 | Yes | No |
| 17659063 | AMORPHOUS SOLID DISPERSIONS | April 2022 | July 2023 | Allow | 15 | 1 | 1 | No | No |
| 17766272 | COMPOSITIONS AND METHODS FOR MEALYBUG MONITORING AND CONTROL | April 2022 | May 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17711444 | COMPOSITIONS WITH FATTY ACIDS AND OPTIONAL CATIONIC COMPOUNDS AND METHODS OF USE | April 2022 | November 2025 | Allow | 44 | 4 | 0 | No | No |
| 17706759 | SUCCINATE DEHYDROGENASE INHIBITORS FOR BREAKING DORMANCY | March 2022 | September 2024 | Allow | 30 | 1 | 1 | No | No |
| 17764773 | NANOFIBRE MATRIX MADE OF NATURAL POLYMERS WITH NATURAL FUNCTIONAL INGREDIENTS FOR COSMETIC PRODUCTS | March 2022 | March 2025 | Abandon | 36 | 2 | 1 | No | No |
| 17655407 | Pearling Agent and Pearlescent Compositions | March 2022 | February 2026 | Abandon | 47 | 6 | 0 | No | No |
| 17655143 | AMORPHOUS SOLID DISPERSIONS | March 2022 | June 2023 | Allow | 15 | 0 | 1 | No | No |
| 17696133 | ANTIMICROBIAL AGENTS AND COMPOSITIONS AND USES THEREOF | March 2022 | November 2024 | Allow | 32 | 0 | 0 | No | No |
| 17691591 | AGENT FOR MODIFYING PIGMENT TO DYE, AND COLORANT COMPOSITION COMPRISING THE DYE | March 2022 | December 2025 | Abandon | 46 | 4 | 1 | No | No |
| 17682658 | DEHYDRATED SOAP AND CLEANER TABLET COMPOSITION | February 2022 | October 2023 | Abandon | 20 | 4 | 0 | Yes | No |
| 17638701 | Compositions Comprising Cannabinoid Ions that are Dissolved in Glycerol | February 2022 | May 2025 | Allow | 39 | 0 | 1 | No | No |
| 17634822 | BENAZOLIN-CHOLINE AND ITS USE IN THE AGROCHEMICAL FIELD | February 2022 | June 2025 | Allow | 40 | 1 | 1 | No | No |
| 17634453 | CANNABIDIOL ORALLY DISINTEGRATING TABLETS | February 2022 | October 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17668678 | COMPOSITION FOR TREATING ATOPY OR PRURITUS COMPRISING N-ACETYL OR N-ACYL AMINO ACID | February 2022 | April 2025 | Allow | 38 | 6 | 0 | Yes | No |
| 17592109 | METHODS OF IMPROVING REPRODUCTIVE AND RESPIRATORY HEALTH | February 2022 | January 2026 | Abandon | 47 | 3 | 1 | Yes | No |
| 17586014 | MIXTURES AND FORMULATIONS COMPRISING AN ALKYL AMMONIUM EDTA SALT | January 2022 | November 2024 | Allow | 34 | 2 | 1 | No | No |
| 17567065 | Tattoo Towelettes | December 2021 | September 2023 | Abandon | 20 | 3 | 0 | Yes | No |
| 17616632 | THREE-DIMENSIONAL STRUCTURE FOR SUPPORTING CELL CULTURE MEDIUM, AND METHOD FOR MANUFACTURING FILM COMPRISING SAME | December 2021 | February 2026 | Abandon | 51 | 2 | 1 | No | No |
| 17614838 | LIQUID COMPOSITION COMPRISING MEFENTRIFLUCONAZOLE | November 2021 | April 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17456510 | AQUEOUS COSMETIC | November 2021 | July 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17531407 | COMPOSITIONS FOR TREATING THE HAIR | November 2021 | February 2024 | Allow | 27 | 1 | 1 | No | No |
| 17611752 | COMPOSITIONS AND METHODS FOR SKIN REJUVENATION | November 2021 | December 2023 | Allow | 25 | 1 | 0 | No | No |
| 17610284 | AGENT FOR PROTECTION AGAINST ATMOSPHERIC POLLUTANTS AND COMPOSITION FOR PROTECTION AGAINST ATMOSPHERIC POLLUTANTS | November 2021 | August 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17595081 | HIGH SPREADING ULV FORMULATIONS FOR FUNGICIDES | November 2021 | March 2026 | Abandon | 52 | 3 | 0 | No | No |
| 17509828 | DETERGENT COMPOSITIONS FOR WASHING URUSHIOL AND METHODS OF TREATING URUSHIOL INDUCED CONTACT DERMATITIS | October 2021 | August 2023 | Allow | 21 | 1 | 0 | No | No |
| 17502172 | SENSORY ENHANCED AND MOISTURIZING HAND SANITIZER FORMULATIONS UTILIZING NON-EMULSION TECHNOLOGIES | October 2021 | March 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17594337 | COMPOSITION FOR A TOPICAL APPLICATION ON THE SKIN | October 2021 | June 2025 | Abandon | 44 | 3 | 1 | Yes | No |
| 17494469 | BALLISTIC DELIVERY METHOD AND SYSTEM FOR INJECTABLE FORMULATIONS | October 2021 | January 2026 | Allow | 51 | 2 | 1 | No | Yes |
| 17492317 | CHOLINE CHLORIDE ADJUVANT FOR FATTY ACID BASED BIOPESTICIDE | October 2021 | November 2025 | Allow | 49 | 5 | 1 | Yes | No |
| 17439284 | MICROPARTICLES BASED ON ESTER DERIVATIVES OF HYALURONAN, METHOD OF PRODUCTION, COMPOSITION COMPRISING THEREOF AND USE THEREOF | September 2021 | August 2023 | Abandon | 23 | 0 | 1 | No | No |
| 17437734 | HERBICIDALLY ACTIVE 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES OF S-CONTAINING CYCLOPENTENYLCARBOXYLIC ESTERS | September 2021 | August 2024 | Allow | 36 | 1 | 0 | No | No |
| 17467274 | METHOD OF PRODUCING ALCOHOL COMPOSITION | September 2021 | September 2025 | Allow | 48 | 4 | 0 | Yes | No |
| 17433719 | PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING PAIN | August 2021 | May 2025 | Allow | 45 | 1 | 1 | No | No |
| 17383516 | KETOCONAZOLE OPHTHALMIC PREPARATIONS CONTAINING TRANS-ETHOSOMAL DRUG NANOPARTICLES | July 2021 | February 2022 | Allow | 6 | 2 | 0 | Yes | No |
| 17424162 | SOLID SOAP | July 2021 | June 2023 | Allow | 23 | 1 | 0 | No | No |
| 17364105 | COMPOSITIONS FOR CONTROLLING ODOR AND ITCH AND METHODS OF AND DEVICES FOR ADMINISTERING SAME | June 2021 | December 2025 | Abandon | 54 | 7 | 0 | Yes | Yes |
| 17360235 | LOW VISCOSITY EMULSION COSMETIC COMPOSITION | June 2021 | March 2024 | Allow | 32 | 1 | 1 | No | No |
| 17416892 | SOLID COSMETIC COMPOSITION CONTAINING ANHYDROUS SPHEROIDS DISPERSED IN A SOLID CONTINUOUS AQUEOUS PHASE | June 2021 | August 2024 | Allow | 38 | 2 | 1 | No | No |
| 17414774 | SUBSTITUTED PYRIDINYLOXYBENZENES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTS | June 2021 | April 2024 | Allow | 34 | 0 | 0 | No | No |
| 17338578 | ANTIFUNGAL COMPOUNDS | June 2021 | September 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17294835 | PREPARATION COMPRISING A DISPERSION OF PHOSPHOLIPIDS AND FATTY ACID SALTS | May 2021 | September 2024 | Allow | 40 | 1 | 1 | No | No |
| 17319221 | METHODS, PARENTERAL PHARMACEUTICAL FORMULATIONS, AND DEVICES FOR THE PREVENTION OF OPIOID OVERDOSE | May 2021 | April 2023 | Abandon | 23 | 3 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CONIGLIO, AUDREA JUNE BUCKLEY.
With a 28.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 22.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CONIGLIO, AUDREA JUNE BUCKLEY works in Art Unit 1617 and has examined 843 patent applications in our dataset. With an allowance rate of 53.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner CONIGLIO, AUDREA JUNE BUCKLEY's allowance rate of 53.6% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CONIGLIO, AUDREA JUNE BUCKLEY receive 2.30 office actions before reaching final disposition. This places the examiner in the 65% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CONIGLIO, AUDREA JUNE BUCKLEY is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +21.9% benefit to allowance rate for applications examined by CONIGLIO, AUDREA JUNE BUCKLEY. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 19.5% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 27.2% of cases where such amendments are filed. This entry rate is in the 38% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 63.6% of appeals filed. This is in the 43% percentile among all examiners. Of these withdrawals, 55.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 61.1% are granted (fully or in part). This grant rate is in the 65% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.8% of allowed cases (in the 73% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.3% of allowed cases (in the 64% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.